ANZCA Council and the FPM Board support an Aboriginal and Torres Strait Islander Voice to Parliament.

ANZCA Council has approved the development of a comprehensive strategy to ensure that the college meets its responsibilities under Te Tiriti o Waitangi, Aotearoa/New Zealand’s founding document.

In a landmark decision, an ACT doctor has been banned for discriminatory and offence behaviour towards a medical colleague.

New this month: Neuromuscular blocker labelling submission, National licensing standards for cosmetic surgery, jaw dislocation podcast.

New this month: Safety alert re shortage of corticosteroids; Australian Government response to report on the rise of allergies/anaphylaxis; report ‘near misses’ to webAIRS; New Zealand National mortality review pānui.

In this update: Our inspiring donors, 163 ANZCA and FPM researchers supported, Foundation grants help ANZCA CTN leverage over $68 million, record number of health equity grant applications, face-to-face events return, Foundation represented at ASMR

The Western Australian Therapeutic Advisory Group and the Western Australian Drug Evaluation Panel have endorsed the delisting of Desflurane from the WA Statewide Medicines Formulary.

ANZCA has been working on a process to support trainees who are unsuccessful in gaining an invitation to the vivas by refunding a portion of their examination fee.

The college has received a number of enquiries from members regarding which Medicare Benefit Schedule (MBS) items are relevant to pain medicine consultations undertaken by trainees.

Updates include: PPRN webinar; Foundation supporter evening; 2024 research grants; global health challenges